Compare Illumina, Inc. (ILMN) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Atlassian Corporation PLC — how do they compare? Illumina, Inc. trades at $191.61 (market cap $27.94B), while Atlassian Corporation PLC trades at $90.28 (market cap $23.67B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| ILMN | TEAM | |
|---|---|---|
Market Cap | $27.94B | $23.67B |
Sector | Health | Technology |
52-Week High | $194.33 | $203.00 |
52-Week Low | $91.00 | $57.15 |
Enterprise Value | $29.33B | $23.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TEAM trades at $96.63, up 3.58% with bullish technical signals and strong analyst support. Revenue growth accelerated to $5.22B in 2025, though net margins remain negative at -4.93%. Recent AI-driven product launches and service collection surpassing $1B ARR highlight innovation momentum. The stock faces resistance near $97 with support at $92.
Outlook remains positive given consensus price target of $114.54 (18.5% upside) and 29 buy ratings. Risks include persistent unprofitability, competitive pressure from Microsoft/ServiceNow, and projected negative cash flow in 2026. Valuation appears reasonable with P/S of 3.96 versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
